Mainz Biomed Expands into Switzerland with New Partnership

Mainz Biomed, a molecular genetics diagnostic firm, is set to expand its reach into Switzerland through a strategic partnership with Labor Team W AG, a diagnostic laboratory based in Goldach. This collaboration will introduce ColoAlert®, a DNA-based colorectal cancer (CRC) screening test, to the Swiss market for the first time. This marks a significant milestone for Mainz Biomed as they broaden their European presence.

ColoAlert® aims to enhance early detection of CRC, a prevalent yet preventable form of cancer with thousands of new cases diagnosed annually in Switzerland. This partnership combines Mainz Biomed’s expertise with Labor Team W’s extensive laboratory services, providing a modern screening test nationwide. The DNA-based test will be available in Switzerland through Labor Team W’s healthcare provider network by Spring 2025.

The partnership underscores the importance of early intervention and prevention in healthcare, aligning with both firms' commitment to improving public health outcomes. ColoAlert® represents the first DNA-based CRC screening test in Europe, propelling Mainz Biomed into a leading role in the personalized healthcare market.